Catriona Yale - Jun 21, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Development Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Jun 21, 2023
Transactions value $
-$1,725,390
Form type
4
Date filed
6/23/2023, 08:06 PM
Previous filing
Jun 15, 2023
Next filing
Aug 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale -$593K -11.3K -14.19% $52.26 68.6K Jun 21, 2023 Direct F1
transaction AKRO Common Stock Sale -$574K -11K -16.03% $52.18 57.6K Jun 22, 2023 Direct F2
transaction AKRO Common Stock Sale -$533K -10.5K -18.22% $50.73 47.1K Jun 23, 2023 Direct F3
transaction AKRO Common Stock Sale -$25.7K -500 -1.06% $51.41 46.6K Jun 23, 2023 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.08 to $52.7125, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3) and (4) to this Form 4.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.81, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.25 to $51.16, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $51.28 to $51.50, inclusive.